LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

LLY

1,071.32

+0.71%↑

JNJ

208.42

+0.07%↑

ABBV

226.26

+0.83%↑

UNH

333.8

+2.13%↑

AZN

91.77

+1.24%↑

Search

PerkinElmer Inc

Ouvert

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-8.6M

47M

Ventes

-21M

699M

P/E

Moyenne du Secteur

51.072

76.798

BPA

1.18

Rendement du dividende

0.28

Marge bénéficiaire

6.675

Employés

11,000

EBITDA

-14M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+14.93% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.28%

2.37%

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

223M

12B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

23%

77%

43 / 374 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 déc. 2025, 23:54 UTC

Actions en Tendance

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 déc. 2025, 23:51 UTC

Résultats

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 déc. 2025, 23:39 UTC

Principaux Mouvements du Marché

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 déc. 2025, 21:40 UTC

Résultats

Nike Sales Tick Up, But China Weakness Persists

18 déc. 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 déc. 2025, 23:37 UTC

Market Talk
Résultats

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 déc. 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 déc. 2025, 23:03 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 déc. 2025, 23:02 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 déc. 2025, 23:00 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 déc. 2025, 22:59 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 déc. 2025, 22:58 UTC

Acquisitions, Fusions, Rachats

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 déc. 2025, 22:57 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 déc. 2025, 22:56 UTC

Acquisitions, Fusions, Rachats

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 déc. 2025, 22:55 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:59 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 déc. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 déc. 2025, 21:35 UTC

Résultats

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 déc. 2025, 21:31 UTC

Résultats

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Greater China Rev Down 17% >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q EPS 53c >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Apparel Rev $3.91B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Equipment Rev $550M >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q N Amer Rev $5.63B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Footwear Rev $7.66B >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 déc. 2025, 21:15 UTC

Résultats

Nike 2Q Greater China Rev $1.42B >NKE

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

14.93% hausse

Prévisions sur 12 Mois

Moyen 111.22 USD  14.93%

Haut 123 USD

Bas 100 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

10 ratings

5

Achat

5

Maintien

0

Vente

Sentiment

By Acuity

43 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat